Epsilon Healthcare Limited AI Stock Analysis
Want to see AU:EPN full AI Analyst Report?
Epsilon Healthcare Limited (EPN) AI Stock Analysis
Epsilon Healthcare Limited
(ASX:EPN)
The overall score of 54 reflects a high-risk, early-stage turnaround. The primary positive driver is strong technical momentum, with the stock price trending well above its moving averages. This is offset by significant fundamental concerns: a highly leveraged balance sheet and a very expensive valuation, with a P/E of 93.3 that leaves no room for error. The company's recent operational stabilization and positive cash flow are encouraging but remain fragile.
Epsilon Healthcare Limited (EPN) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 3.89M
- Dividend Yield
- ―
- Average Volume (3M)
- 206.59K
- Price to Earnings (P/E)
- 76.7
- Beta (1Y)
- -0.30
- Revenue Growth
- 121.40%
- EPS Growth
- ―
- Country
- Australia
- Employees
- 14
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Epsilon Healthcare Limited Business Overview & Revenue Model
Company Description
Epsilon Healthcare Limited operates as an Australian-based healthcare and pharmaceutical firm, with significant operations also extending into Canada. Established in 2016 and headquartered in Sydney, the company specializes in several areas: manufact...
How the Company Makes Money
null
Epsilon Healthcare Limited Financial Statement Overview
Summary
Financial performance shows a nascent turnaround with positive TTM net income and strong cash flow recovery, but is weighed down by a highly leveraged balance sheet and compressed gross margins. The overall picture is one of stabilization with significant fragility.
Income Statement
45NeutralBalance Sheet
35NegativeCash Flow
65Positive| Breakdown | TTM | Dec 2025 | Jun 2025 | Dec 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.37M | 9.39M | 5.60M | 6.65M | 7.11M | 5.50M |
| Gross Profit | 6.92M | 2.09M | 4.17M | 4.81M | 725.85K | 2.06M |
| EBITDA | -694.10K | -1.86M | -2.13M | -937.07K | -10.86M | -8.03M |
| Net Income | 96.58K | -1.28M | -3.25M | -1.09M | -13.29M | -9.24M |
Balance Sheet | ||||||
| Total Assets | 19.47M | 17.87M | 22.26M | 14.41M | 20.50M | 30.55M |
| Cash, Cash Equivalents and Short-Term Investments | 1.29M | 242.86K | 1.57M | 343.01K | 809.60K | 2.34M |
| Total Debt | 8.69M | 10.35M | 7.88M | 3.45M | 3.20M | 4.44M |
| Total Liabilities | 15.59M | 15.95M | 11.57M | 6.87M | 11.23M | 10.98M |
| Stockholders Equity | 3.88M | 1.91M | 10.70M | 7.54M | 9.27M | 19.57M |
Cash Flow | ||||||
| Free Cash Flow | 975.73K | -3.30M | -3.50M | -803.47K | -3.10M | -6.18M |
| Operating Cash Flow | 1.12M | -3.13M | -3.41M | -703.37K | -2.57M | -5.43M |
| Investing Cash Flow | -703.93K | 6.29M | -97.73K | -99.12K | -529.40K | -737.59K |
| Financing Cash Flow | 131.29K | -4.48M | 4.73M | 335.91K | 1.61M | 1.47M |
Epsilon Healthcare Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EPN, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of 0.00 indicates Negative momentum. The RSI at 49.29 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:EPN.
Epsilon Healthcare Limited Peers Comparison
Overall Rating
AU:VLS77Outperform
AU:MVP60Neutral
AU:EPN54Neutral
AU:LGP51.5Neutral
AU:IDT43Neutral
AU:PKP39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 77Outperform | AUD 142.75M | 13.00 | 19.91% | 5.58% | 12.19% | 22.36% | |
| 60Neutral | AUD 46.19M | 75.89 | 1.13% | ― | 8.99% | 450.00% | |
| 54Neutral | AUD 9.73M | 76.67 | 3.34% | ― | 121.40% | ― | |
| 52Neutral | AUD 54.65M | -14.35 | -1.67% | ― | 15.21% | -141.82% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 43Neutral | AUD 19.03M | -7.19 | -13.81% | ― | 5.93% | 66.32% | |
| 39Underperform | AUD 18.75M | -5.07 | 4388.00% | ― | -19.73% | 50.34% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:EPN | Epsilon Healthcare Limited | 0.02 | -0.00 | -4.17% | |
| AU:VLS | Vita Life Sciences Limited | 2.60 | 0.29 | 12.70% | |
| AU:LGP | Little Green Pharma Ltd. | 0.07 | -0.07 | -52.86% | |
| AU:MVP | Medical Developments International Limited | 0.42 | -0.10 | -18.27% | |
| AU:PKP | Althea Group Holdings Ltd. | 0.01 | -0.01 | -35.00% | |
| AU:IDT | IDT Australia Limited | 0.05 | -0.01 | -22.03% |
Epsilon Healthcare Limited Corporate Events
Epsilon Healthcare lifts quarterly receipts 34% as diversified platform gains scale
Epsilon Healthcare Limited reported strong growth for the quarter ended 30 September 2026, with customer receipts of $3.9 million, up 34 percent on the prior year’s corresponding quarter. The performance was driven by rising demand across its contrac...
Epsilon Healthcare lifts revenue and builds integrated medicinal cannabis platform
Epsilon Healthcare reported a sharp turnaround in the first half of 2026, with revenue rising 123% to $7.59 million, positive EBITDA of $255,000, and net operating cash flow of $1.03 million, helped by stronger operating performance and lower one-off...
Epsilon Healthcare Clarifies Managing Director Loan Was Unsecured
Epsilon Healthcare has clarified that a loan from its Managing Director, previously described as “secured” in several quarterly Appendix 4C cash flow reports, was in fact unsecured at all times. The company confirmed that no security interest or char...
Epsilon Healthcare Director Boosts Equity Stake Through On-Market Share Purchase
Epsilon Healthcare Limited has disclosed a change in the shareholding of director Zoe Hutchings, in line with ASX listing rule requirements. The filing details her direct interests in fully paid ordinary shares and confirms that there were no changes...
Epsilon Healthcare Director Alan Beasley Boosts Shareholding via On-Market Purchases
Epsilon Healthcare Limited has disclosed a change in the holdings of director Alan Preston Beasley, who increased his direct stake in the company through on-market purchases. Over several transactions on 3, 4 and 10 September 2026, Beasley acquired 1...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 24, 2026
